{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:56:34Z","timestamp":1790434594019,"version":"4.1.0"},"reference-count":79,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T00:00:00Z","timestamp":1700697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Atherosclerosis is a chronic inflammatory disease characterized by lipid and inflammatory cell deposits in the inner layer of large- and medium-sized elastic and muscular arteries. Diabetes mellitus (DM) significantly increases the risk of cardiovascular diseases and the overall and cardiovascular mortality, and it is a pro-atherogenic factor that induces atherosclerosis development and\/or accelerates its progression through a multifactorial process. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new class of drugs, belonging to the armamentarium to fight type 2 DM, that have shown robust reductions in atherosclerotic events and all-cause mortality in all studies. Preclinical studies have shown that GLP-1RAs play a role in the immunomodulation of atherosclerosis, affecting multiple pathways involved in plaque development and progression. In this review, we wanted to explore the translational power of such preclinical studies by analyzing the most recent clinical trials investigating the atheroprotective effect of GLP-1RAs.<\/jats:p>","DOI":"10.3390\/biom13121695","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T11:31:25Z","timestamp":1700739085000},"page":"1695","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?"],"prefix":"10.3390","volume":"13","author":[{"given":"Dalgisio","family":"Lecis","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1878-8871","authenticated-orcid":false,"given":"Francesca Romana","family":"Prandi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9476-9168","authenticated-orcid":false,"given":"Lucy","family":"Barone","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3648-9277","authenticated-orcid":false,"given":"Martina","family":"Belli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"},{"name":"Cardiovascular Imaging Unit, San Raffaele Scientific Institute, 20132 Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Sergi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Longo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4037-7561","authenticated-orcid":false,"given":"Saverio","family":"Muscoli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Romeo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences, 00131 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federici","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatios","family":"Lerakis","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barill\u00e0","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Systems Medicine, Tor Vergata University, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(1983). Classics in arteriosclerosis research: On experimental cholesterin steatosis and its significance in the origin of some pathological processes by N. Anitschkow and S. Chalatow, translated by Mary Z. Pelias, 1913. Arterioscler. Dallas Tex, 3, 178\u2013182.","DOI":"10.1161\/01.ATV.3.2.178"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0021-9258(19)51290-X","article-title":"Ultracentrifugal studies of lipoproteins of human serum","volume":"179","author":"Gofman","year":"1949","journal-title":"J. Biol. Chem."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1126\/science.111.2877.166","article-title":"The role of lipids and lipoproteins in atherosclerosis","volume":"111","author":"Gofman","year":"1950","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1152\/physrev.1954.34.3.589","article-title":"Lipoproteins, coronary heart disease, and atherosclerosis","volume":"34","author":"Gofman","year":"1954","journal-title":"Physiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1073\/pnas.70.10.2804","article-title":"Familial hypercholesterolemia: Identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol","volume":"70","author":"Goldstein","year":"1973","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.18901.1","article-title":"Inflammation in atherosclerotic cardiovascular disease","volume":"8","author":"Shah","year":"2019","journal-title":"F1000Research"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014An Inflammatory Disease","volume":"340","author":"Ross","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"2525","article-title":"Inflammation during the life cycle of the atherosclerotic plaque","volume":"117","author":"Libby","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Boren","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/01.ATV.12.5.569","article-title":"Effect of arterial proteoglycans and glycosaminoglycans on low density lipoprotein oxidation and its uptake by human macrophages and arterial smooth muscle cells","volume":"12","author":"Camejo","year":"1992","journal-title":"Arterioscler. Thromb. J. Vasc. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kattoor, A.J., Goel, A., and Mehta, J.L. (2019). LOX-1: Regulation, Signaling and Its Role in Atherosclerosis. Antioxidants, 8.","DOI":"10.3390\/antiox8070218"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2017.10.002","article-title":"Contribution of lectin-like oxidized low-density lipoprotein receptor-1 and LOX-1 modulating compounds to vascular diseases","volume":"107","author":"Hofmann","year":"2017","journal-title":"Vasc. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4B","DOI":"10.1016\/S0002-9149(02)03267-8","article-title":"Mechanisms of plaque stabilization with statins","volume":"91","author":"Libby","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: A Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.ATV.12.6.647","article-title":"George Lyman Duff Memorial Lecture. Atherogenesis in diabetes","volume":"12","author":"Bierman","year":"1992","journal-title":"Arterioscler. Thromb. J. Vasc. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/dmr.5610030206","article-title":"Diabetes and atherosclerosis: An epidemiologic view","volume":"3","author":"Laakso","year":"1987","journal-title":"Diabetes Metab. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10741-021-10200-y","article-title":"Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: Molecular abnormalities and phenotypical variants","volume":"28","author":"Prandi","year":"2023","journal-title":"Heart Fail. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Prandi, F.R., Lecis, D., Illuminato, F., Milite, M., Celotto, R., Lerakis, S., Romeo, F., and Barill\u00e0, F. (2022). Epigenetic Modifications and Non-Coding RNA in Diabetes-Mellitus-Induced Coronary Artery Disease: Pathophysiological Link and New Therapeutic Frontiers. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094589"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"838410","DOI":"10.3389\/fendo.2022.838410","article-title":"Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00592-023-02088-x","article-title":"Microbiota-gut-brain axis: Relationships among the vagus nerve, gut microbiota, obesity, and diabetes","volume":"60","author":"Longo","year":"2023","journal-title":"Acta Diabetol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pandey, S., Mangmool, S., and Parichatikanond, W. (2023). Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective. Pharmaceuticals, 16.","DOI":"10.3390\/ph16060836"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: Highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MOL.0000000000000293","article-title":"Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism","volume":"27","author":"Lutz","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/dom.13153","article-title":"Incretins: B eyond type 2 diabetes","volume":"20","author":"Dandona","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/dom.12998","article-title":"A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus","volume":"19","author":"Owens","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Gumieniczek, A., and Berecka-Rycerz, A. (2023). Metabolism and Chemical Degradation of New Antidiabetic Drugs: A Review of Analytical Approaches for Analysis of Glutides and Gliflozins. Biomedicines, 11.","DOI":"10.3390\/biomedicines11082127"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"170939","DOI":"10.1016\/j.peptides.2023.170939","article-title":"An update on peptide-based therapies for type 2 diabetes and obesity","volume":"161","author":"Bailey","year":"2023","journal-title":"Peptides"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00592-023-02097-w","article-title":"Glucose variability: A new risk factor for cardiovascular disease","volume":"60","author":"Belli","year":"2023","journal-title":"Acta Diabetol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.13955","article-title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","first-page":"891","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"376","author":"Marso","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes-state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: An updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","article-title":"Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus","volume":"64","author":"Ferdinand","year":"2014","journal-title":"Hypertension"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/eurheartj\/ehac395","article-title":"Hypertension management in patients with cardiovascular comorbidities","volume":"44","author":"Lauder","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6518221","DOI":"10.1155\/2021\/6518221","article-title":"The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes","volume":"2021","author":"Yaribeygi","year":"2021","journal-title":"J. Diabetes Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): Effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1470320316677918","DOI":"10.1177\/1470320316677918","article-title":"Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction","volume":"17","author":"Le","year":"2016","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/HYPERTENSIONAHA.120.14868","article-title":"Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control: Role of Proximal Tubule Na+\/H+ Exchanger Isoform 3, Renal Angiotensin II, and Insulin Sensitivity","volume":"76","author":"Martins","year":"2020","journal-title":"Hypertension"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jdiacomp.2016.08.018","article-title":"Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis","volume":"32","author":"Waldrop","year":"2018","journal-title":"J. Diabetes Complications"},{"key":"ref_49","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study","volume":"102","author":"Petit","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","article-title":"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: A systematic review and network meta-analysis","volume":"37","author":"Sun","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12933-019-0945-7","article-title":"Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: A randomized, placebo-controlled, cross-over, double-blind clinical trial","volume":"18","author":"Peradze","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","article-title":"GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","volume":"17","author":"Sposito","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/01.mol.0000203192.45649.ba","article-title":"Genetics and molecular biology: Macrophage ACAT depletion-mechanisms of atherogenesis","volume":"17","author":"Akopian","year":"2006","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12974-023-02700-5","article-title":"Role of acyl-coenzyme A: Cholesterol transferase 1 (ACAT1) in retinal neovascularization","volume":"20","author":"Zaidi","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1194\/jlr.M500101-JLR200","article-title":"Acyl-coenzyme A: Cholesterol acyltransferase promotes oxidized LDL\/oxysterol-induced apoptosis in macrophages","volume":"46","author":"Freeman","year":"2005","journal-title":"J. Lipid Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1161\/01.CIR.0000155236.25081.9B","article-title":"Systemic Acyl-CoA: Cholesterol acyltransferase inhibition reduces inflammation and improves vascular function in hypercholesterolemia","volume":"111","author":"Kharbanda","year":"2005","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2013.12.015","article-title":"A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis","volume":"54","author":"Tashiro","year":"2014","journal-title":"Peptides"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"ref_59","first-page":"206","article-title":"Mechanisms of cell signaling by the scavenger receptor CD36: Implications in atherosclerosis and thrombosis","volume":"121","author":"Silverstein","year":"2010","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE\u2212\/\u2212 and LDLr\u2212\/\u2212 Mice by a Mechanism That Includes Inflammatory Pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-018-0691-2","article-title":"Bone markers and cardiovascular risk in type 2 diabetes patients","volume":"17","author":"Zwakenberg","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_62","first-page":"353","article-title":"Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo","volume":"152","author":"Giachelli","year":"1998","journal-title":"Am. J. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12933-017-0626-3","article-title":"Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","volume":"16","author":"Bruen","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1124\/jpet.119.258343","article-title":"Liraglutide Attenuates Preestablished Atherosclerosis in Apolipoprotein E-Deficient Mice via Regulation of Immune Cell Phenotypes and Proinflammatory Mediators","volume":"370","author":"Bruen","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5568159","DOI":"10.1155\/2021\/5568159","article-title":"Effect of GLP-1\/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis","volume":"2021","author":"Yang","year":"2021","journal-title":"Med. Inflamm."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.abb.2019.07.008","article-title":"Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation","volume":"671","author":"Luo","year":"2019","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Muscoli, C., Ilari, S., Mollace, V., Della Morte, D., Bellia, A., and Di Daniele, N. (2023). Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021646"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00325481.2022.2147326","article-title":"Efficacy and safety of semaglutide for weight management: Evidence from the STEP program","volume":"134","author":"Amaro","year":"2022","journal-title":"Postgrad. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Liao, C., Liang, X., Zhang, X., and Li, Y. (2023). The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0289616"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/oby.23621","article-title":"Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics","volume":"31","author":"Lingvay","year":"2023","journal-title":"Obesity"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2174\/1389450043345245","article-title":"A new Alzheimer\u2019s disease interventive strategy: GLP-1","volume":"5","author":"Perry","year":"2004","journal-title":"Curr. Drug Targets"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","article-title":"Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?","volume":"118","author":"Bassil","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101470","DOI":"10.1016\/j.diabet.2023.101470","article-title":"GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes","volume":"49","author":"Monney","year":"2023","journal-title":"Diabetes Metab."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Jantrapirom, S., Nimlamool, W., Chattipakorn, N., Chattipakorn, S., Temviriyanukul, P., Inthachat, W., Govitrapong, P., and Potikanond, S. (2020). Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051725"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrneurol.2017.185","article-title":"Brain insulin resistance in type 2 diabetes and Alzheimer disease: Concepts and conundrums","volume":"14","author":"Arnold","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Laurindo, L.F., Barbalho, S.M., Guiguer, E.L., da Silva Soares de Souza, M., de Souza, G.A., Fidalgo, T.M., Ara\u00fajo, A.C., de Souza Gonzaga, H.F., de Bortoli Teixeira, D., and de Oliveira Silva Ullmann, T. (2022). GLP-1a: Going beyond Traditional Use. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020739"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"(1998). Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339, 1349\u20131357.","DOI":"10.1056\/NEJM199811053391902"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/12\/1695\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:28:38Z","timestamp":1760131718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/13\/12\/1695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":79,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["biom13121695"],"URL":"https:\/\/doi.org\/10.3390\/biom13121695","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}